Get started
Author

Emily M. Martyn

Observed names: E. Martyn, Emily M Martyn, Emily Martyn, Martyn, Emily
Observed institutions: Rutgers, The State University of New Jersey, University College London Hospitals NHS Foundation Trust, Central and North West London NHS Foundation Trust, The Francis Crick Institute, London School of Hygiene & Tropical Medicine, Hospital for Tropical Diseases, Infectious Diseases Institute, Mortimer Market Centre, North Middlesex University Hospital NHS Trust, North Middlesex Hospital, Rutgers Health, University College London, Imperial College London, Middlesex University London, Makerere University
ORCID: 0000-0003-4981-9298
Observed ORCID: 0000-0003-4981-9298
OpenAlex ID: A5004729258
The forgotten people: Hepatitis B virus (HBV) infection as a priority for the inclusion health agenda
2023 · Emily Martyn, Sarah Eisen, et al. · eLife · 86
High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial
2021 · Fiona V Cresswell, David B Meya, et al. · Clinical Infectious Diseases · 79
Standardized Urine-Based Tuberculosis (TB) Screening With TB-Lipoarabinomannan and Xpert MTB/RIF Ultra in Ugandan Adults With Advanced Human Immunodeficiency Virus Disease and Suspected Meningitis
2020 · Fiona V Cresswell, Jayne Ellis, et al. · Open Forum Infectious Diseases · 37
PDF
Evaluation of Serum Cryptococcal Antigen Testing Using Two Novel Semiquantitative Lateral Flow Assays in Persons with Cryptococcal Antigenemia
2020 · Caleb Skipper, Kiiza Tadeo, et al. · Journal of Clinical Microbiology · 37
Evaluation of the Diagnostic Performance of a Semiquantitative Cryptococcal Antigen Point-of-Care Assay among HIV-Infected Persons with Cryptococcal Meningitis
2021 · Kiiza Kandole Tadeo, Audrey Nimwesiga, et al. · Journal of Clinical Microbiology · 32
High dose oral rifampicin to improve survival from adult tuberculous meningitis: A randomised placebo-controlled double-blinded phase III trial (the HARVEST study)
2020 · Suzaan Marais, Fiona V Cresswell, et al. · Wellcome Open Research · 24
PDF
Peer support for people living with hepatitis B virus—A foundation for treatment expansion
2024 · Louise O. Downs, Kenneth Kabagambe, et al. · Journal of Viral Hepatitis · 22
PDF
A systematic review and meta-analysis of the risk of hepatitis B virus (HBV) resistance in people treated with entecavir or tenofovir
2024 · Sheila F. Lumley, Marion Delphin, et al. · Journal of Clinical Virology · 20
Social, clinical and biological barriers to hepatitis B virus suppression with nucleos/tide analogue therapy: who is at risk and what should we do about it?
2024 · Yu Ri Im, Khadija Said Mohammed, et al. · Sexually Transmitted Infections · 19
PDF
Cytomegalovirus viremia as a risk factor for mortality in HIV-associated cryptococcal and tuberculous meningitis
2022 · Caleb P. Skipper, Katherine Huppler Hullsiek, et al. · International Journal of Infectious Diseases · 19
High dose oral rifampicin to improve survival from adult tuberculous meningitis: A randomised placebo-controlled double-blinded phase III trial (the HARVEST study)
2019 · Suzaan Marais, Fiona V Cresswell, et al. · Wellcome Open Research · 17
Reducing broad-spectrum antibiotic use in intensive care unit between first and second waves of COVID-19 did not adversely affect mortality
2022 · X.H.S. Chan, C.J. O'Connor, et al. · Journal of Hospital Infection · 15
Cerebrospinal Fluid Bacillary Load by Xpert MTB/RIF Ultra Polymerase Chain Reaction Cycle Threshold Value Predicts 2-Week Mortality in Human Immunodeficiency Virus–Associated Tuberculous Meningitis
2020 · Emily M Martyn, Ananta S Bangdiwala, et al. · Clinical Infectious Diseases · 14
PDF
Hepatitis B virus (HBV) screening, linkage and retention-in-care in inclusion health populations: Evaluation of an outreach screening programme in London
2023 · Emily Martyn, Sive O’Regan, et al. · Journal of Infection · 12
PDF
Bacterial Coinfection in COVID-19
2020 · Eliza Gil, Emily Martyn, et al. · Clinical Infectious Diseases · 10
PDF
Strongyloides, HTLV-1 and small bowel obstruction
2019 · Emily Martyn, Betty Gration, et al. · BMJ Case Reports · 9
Yersinia pseudotuberculosis: an unexpected cause of fever and a hot joint
2020 · Emily Martyn, Jack Heward, et al. · BMJ Case Reports · 6
Disproportionate impact of SARS-CoV-2 on ethnic minority and frontline healthcare workers: A cross-sectional seroprevalence survey at a North London hospital
2021 · Emily M. Martyn, Heather Whitaker, et al. · Journal of Infection · 5
PDF
Diagnosing and defining MASLD in people living with chronic hepatitis B
2026 · Emily Martyn, Alejandro Arenas-Pinto, et al. · Communications Medicine · 3
PDF
Multiple risk factors for persistent HBV viraemia in an adult receiving nucleos/tide analogue therapy
2024 · Sheila Lumley, Maeve Barlow, et al. · Sexually Transmitted Infections · 3
PDF
A Journey of Hope: giving research participants a voice to share their experiences and improve community engagement around advanced HIV disease in Uganda
2020 · Fiona V. Cresswell, John Kasibante, et al. · AAS Open Research · 3
COVID-19 and the HIV care continuum in Uganda: minimising collateral damage
2021 · Enock Kagimu, Emily M. Martyn, et al. · Open Research Africa · 2
The interaction between chronic hepatitis B (CHB) and Metabolic dysfunction-associated steatotic liver disease (MASLD) in a diverse central London population
2026 · Emily Martyn, Claire Mullender, et al. · medRxiv · 1
PDF
AMSTAR 2 excel tool
2026 · Martyn, Emily · Figshare · 1
What is the impact of metabolic dysfunction-associated steatotic liver disease (MASLD) on outcomes in people living with chronic hepatitis B (CHB)? An umbrella review protocol - PRISMA 2020 checklist
2026 · Martyn, Emily · Figshare · 1
Works count: 71
Citation count: 481
H-index: 13
I10-index: 15
Year
Topic
Type